Terminal breast cancer patient now cancer-free, thanks to experimental therapy

ACT immunotherapy cures terminal breast cancer patient

Cancer patient given just 3 months to live is cured by experimental treatment

The life of a woman suffering from an incurable breast cancer at the terminal stage had been saved by an experimental treatment developed by us researchers, reports the BBC. The results are sure to accelerate the decline in chemotherapy for the disease.

"It is not only a benefit to patients in not undergoing unnecessary toxic treatment, but it provides a level of confidence and it reduces the distress in how they make a decision", says Dr. Stephen Chia, Medical Oncologist in BC Cancer's Vancouver centre and Head of the Province's Breast Tumor group.

Lead investigator Steven Rosenberg said: "Because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer". "They are going to change treatment - and remove uncertainty for women making decisions".

Before the new study results, Dr. Harsha Vardhana, an oncologist at Erlanger Oncology and Hematology, said he would prepare patients for the possibility that the genetic test might not provide a clear answer.

Do you know someone who has had breast cancer?

It has been known for long that women who fall between 0 and 10 have a very low risk of recurrence and those who fall between 26 and 100 are at high risk. Other patients may change their treatment approach based on the results.

According to AOL, TAILORx "followed 9,717 women with early-stage disease, ages 18 to 75, with estrogen-receptor-positive, HER2-negative cancers that had not spread to the lymph nodes - cases where doctors have been unsure whether chemo would be helpful".

On the 6th of the month, CBS 6 and VCU Massey Cancer Center remind women to contact their buddy to remind them to conduct a monthly breast self-exam. The treatment involves the sequenced genome of the cancer in order to recognize and spot that which elements of the cancer cells may be "visible" to the patient's immune system. A score of 26 and above was considered high risk, and those women received both chemotherapy and hormonal treatment.

'Do you want some?': Wealdstone Raider crashes Tyson Fury presser
I know who I am, where I've come from, where I've been, and I know what destination I'm heading towards. I've been a goldfish trapped in a tank and now I'm getting released back into the river.

The big outstanding question was: What should women with "midrange" scores get?

"We would always argue, 'Should we give them chemotherapy or not?'" Vardhana said.

The search is on for a center director to lead a group of about 30 researchers. Targeted cancer therapies differ in several ways from standard chemotherapy.

Who benefits the most from this study?

He is Kropp's doctor and is excited at not just the results, but knowing local women were part of it.

Certain women 50 or younger did benefit from chemo; slightly fewer cases of cancer spreading far beyond the breast occurred among some of them given chemo, depending on their risk scores on the gene test.

It has been said that "into each life, a little rain must fall", but for 52-year-old Judy Perkins, it's been a monsoon.

Latest News